- About
- Home
- Introduction
- Statistics
- Programs
- Dignet
- Gene
- GenePair
- BioSummarAI
- Help & Docs
- Documents
- Help
- FAQs
- Links
- Acknowledge
- Disclaimer
- Contact Us
Gene Information
Gene symbol: EPHX2
Gene name: epoxide hydrolase 2, cytoplasmic
HGNC ID: 3402
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | ACE | 1 hits |
| 2 | AGT | 1 hits |
| 3 | CYP11B2 | 1 hits |
| 4 | CYP2B6 | 1 hits |
| 5 | CYP3A4 | 1 hits |
| 6 | EPHX1 | 1 hits |
| 7 | NR3C2 | 1 hits |
| 8 | SCN1A | 1 hits |
| 9 | TBXAS1 | 1 hits |
| 10 | VIPR2 | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 24125961 | Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. |
| 2 | 24125961 | In this study, we sought to investigate the effects of genetic polymorphisms of the microsomal epoxide hydrolase (EPHX1), the sodium channel α subunit type I (SCN1A) and the cytochrome P450 3A4 (CYP3A4) genes on plasma CBZ concentrations and pharmacoresistance in Chinese patients with epilepsy. |
| 3 | 24125961 | The EPHX1 c.337T>C, c.416A>G, SCN1A IVS5-91G>A or CYP3A4*1G polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism approach or direct DNA sequencing in 83 Chinese patients treated with CBZ monotherapy. |
| 4 | 24125961 | There were no associations between all the studied genotypes involving EPHX1 c.337T>C, c.416A>G, SCN1A IVS5-91G>A or CYP3A4*1G polymorphisms and pharmacoresistance in this patient cohort. |
| 5 | 25767291 | New drug classes, eg, inhibitors of vasopeptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of natriuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mineralocorticoid receptor antagonist are in phase II/III of development, while inhibitors of aminopeptidase A, dopamine β-hydroxylase, and the intestinal Na(+)/H(+) exchanger 3, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1-7)/Mas receptor axis and vaccines directed toward angiotensin II and its type 1 receptor are in phase I or preclinical development. |